Literature DB >> 32038922

Minimal residual disease after radical surgery in EGFR-mutant non-small cell lung cancer.

Katsuhiro Masago1, Yoshitsugu Horio2, Shiro Fujita1, Yasushi Yatabe1,3.   

Abstract

Entities:  

Year:  2019        PMID： 32038922      PMCID： PMC6987333          DOI： 10.21037/tlcr.2019.09.09

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  18 in total

1.  Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.

Authors:  Yosuke Togashi; Katsuhiro Masago; Satohiro Masuda; Tomoyuki Mizuno; Masahide Fukudo; Yasuaki Ikemi; Yuichi Sakamori; Hiroki Nagai; Young Hak Kim; Toshiya Katsura; Michiaki Mishima
Journal:  Cancer Chemother Pharmacol       Date:  2012-07-18       Impact factor: 3.333

2.  Modification of the blood-brain barrier permeability by vinorelbine: effect of intracarotid infusion compared with intravenous infusion.

Authors:  C Mouchard-Delmas; B Gourdier; R Vistelle; M Wiczewski
Journal:  Anticancer Drugs       Date:  1996-02       Impact factor: 2.248

Review 3.  New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.

Authors:  Geoffrey R Oxnard; Maria E Arcila; Juliann Chmielecki; Marc Ladanyi; Vincent A Miller; William Pao
Journal:  Clin Cancer Res       Date:  2011-07-20       Impact factor: 12.531

Review 4.  Adjuvant treatment of non-small cell lung cancer: focus on targeted therapy.

Authors:  Marco Tazza; Giulio Metro
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

5.  Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

Authors:  Karen Kelly; Nasser K Altorki; Wilfried E E Eberhardt; Mary E R O'Brien; David R Spigel; Lucio Crinò; Chun-Ming Tsai; Joo-Hang Kim; Eun Kyung Cho; Philip C Hoffman; Sergey V Orlov; Piotr Serwatowski; Jiuzhou Wang; Margaret A Foley; Julie D Horan; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

6.  Distribution of cisplatin in perilymph and cerebrospinal fluid after intravenous administration in the guinea pig.

Authors:  G Laurell; A Andersson; B Engström; H Ehrsson
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 7.  Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions.

Authors:  Young Kwang Chae; Michael S Oh
Journal:  J Thorac Oncol       Date:  2018-10-06       Impact factor: 15.609

8.  Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

Authors:  Egbert F Smit; Jan P A M van Meerbeeck; Pilar Lianes; Channa Debruyne; Catherine Legrand; Franz Schramel; Hans Smit; Rabab Gaafar; Bonne Biesma; Chris Manegold; Niels Neymark; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2003-11-01       Impact factor: 44.544

9.  Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Authors:  Jhanelle E Gray; Isamu Okamoto; Virote Sriuranpong; Johan Vansteenkiste; Fumio Imamura; Jong Seok Lee; Yong-Kek Pang; Manuel Cobo; Kazuo Kasahara; Ying Cheng; Naoyuki Nogami; Eun Kyung Cho; Wu Chou Su; Guili Zhang; Xiangning Huang; Xiaocheng Li-Sucholeiki; Brian Lentrichia; Simon Dearden; Suzanne Jenkins; Matilde Saggese; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  Clin Cancer Res       Date:  2019-08-22       Impact factor: 12.531

10.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.